Recent developments in the treatment of osteoarthritis with NSAIDs

References

• Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000;133:635-46
   PubMed Web of Science ®Google Scholar
• Attur M, Samuels J, Krasnokutsky S, et al. Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence?. Best Pract Res Clin Rheumatol 2010;24:71-9
   PubMed Web of Science ®Google Scholar
• Courtney CA, Lewek MD, Witte PO, et al. Heightened flexor withdrawal responses in subjects with knee osteoarthritis. J Pain 2009;10:1242-9
   PubMed Web of Science ®Google Scholar
• Courtney CA, Witte PO, Chmell SJ, et al. Heightened flexor withdrawal response in individuals with knee osteoarthritis is modulated by joint compression and joint mobilization. J Pain 2010;11:179-85
   PubMed Web of Science ®Google Scholar
• McHugh GA, Luker KA, Campbell M, et al. Pain, physical functioning and quality of life of individuals awaiting total joint replacement: a longitudinal study. J Eval Clin Pract 2008;14:19-26
   PubMed Web of Science ®Google Scholar
• Jakobsson U, Hallberg IR. Quality of life among older adults with osteoarthritis: an explorative study. J Gerontol Nurs 2006;32:51-60
   PubMed Web of Science ®Google Scholar
• Parmelee PA, Harralson TL, Smith LA, et al. Necessary and discretionary activities in knee osteoarthritis: do they mediate the pain-depression relationship?. Pain Med 2007;8:449-61
   PubMed Web of Science ®Google Scholar
• Scopaz KA, Piva SR, Wisniewski S, et al. Relationships of fear, anxiety, and depression with physical function in patients with knee osteoarthritis. Arch Phys Med Rehabil 2009;90:1866-73
   PubMed Web of Science ®Google Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15
   PubMed Web of Science ®Google Scholar
• Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003;163:169-78
   PubMed Web of Science ®Google Scholar
• Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 2004;63:1028-34
   PubMed Web of Science ®Google Scholar
• Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 2004;51:746-54
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331-4
   PubMed Web of Science ®Google Scholar
• Loux JJ, Smith S, Salem H. Antiinflammatory activity: evaluation of a new screening procedure. Inflammation 1977;2:125-30
   PubMedGoogle Scholar
• Heard K, Green JL, Bailey JE, et al. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007;26:283-90
   PubMed Web of Science ®Google Scholar
• Nüesch E, Rutjes AW, Husni E, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009;CD003115
   Google Scholar
• Goodwin JL, Kraemer JJ, Bajwa ZH. The use of opioids in the treatment of osteoarthritis: when, why, and how?. Curr Rheumatol Rep 2009;11:5-14
   PubMedGoogle Scholar
• Smith HS, Kirsh KL, Passik SD. Chronic opioid therapy issues associated with opioid abuse potential. J Opioid Manag 2009;5:287-300
   PubMedGoogle Scholar
• U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2009
   Google Scholar
• Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clin Toxicol (Phila) 2007;45:144-51
   PubMed Web of Science ®Google Scholar
• Fishman SM, Papazian JS, Gonzalez S, et al. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med 2004;5:309-24
   PubMed Web of Science ®Google Scholar
• Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-60
   PubMed Web of Science ®Google Scholar
• Magni G. The use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs 1991;42:730-48
   Google Scholar
• Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992;49:205-19
   PubMed Web of Science ®Google Scholar
• Kivitz A, Fairfax M, Sheldon EA, et al. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Clin Ther 2008;30:2366-77
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Posner M, Lawrence ID. High strength capsaicin cream for osteoarthritis pain: rapid onset of action and improved efficacy with twice daily dosing. J Clin Rheumatol 1995;1:268-73
   PubMedGoogle Scholar
• Agency for Healthcare Research and Quality U.S. Department of Health and Human Services. Choosing nonopioid analgesics for osteoarthritis: clinician summary guide. J Pain Palliat Care Pharmacother 2009;23:433-57
   PubMedGoogle Scholar
• Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11:125-38
   PubMed Web of Science ®Google Scholar
• Biswal S, Medhi B, Pandhi P. Longterm efficacy of topical nonsteroidal antiinflammatory drugs in knee osteoarthritis: metaanalysis of randomized placebo controlled clinical trials. J Rheumatol 2006;33:1841-4
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009;103:1227-37
   PubMed Web of Science ®Google Scholar
• Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet 2007;370:2138-51
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28, 28 e1-5
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009;8:669-81
   PubMed Web of Science ®Google Scholar
• Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin 2008;24:2967-92
   PubMed Web of Science ®Google Scholar
• Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010;50:50-61
   PubMed Web of Science ®Google Scholar
• Tanojo H, Wester RC, Shainhouse JZ, et al. Diclofenac metabolic profile following in vitro percutaneous absorption through viable human skin. Eur J Drug Metab Pharmacokinet 1999;24:345-51
   PubMed Web of Science ®Google Scholar
• Bueno H, Bardaji A, Patrignani P, et al. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 2010;105:1102-6
   PubMed Web of Science ®Google Scholar
• Stichtenoth DO, Wagner B, Frolich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 1997;45:44-9
   PubMed Web of Science ®Google Scholar
• Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 1999;36:115-26
   Google Scholar
• Hawkey C, Kahan A, Steinbrück K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37:937-45
   PubMedGoogle Scholar
• Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996;35(Suppl 1):39-43
   PubMedGoogle Scholar
• Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med 2000;160:2947-54
   PubMed Web of Science ®Google Scholar
• Valat JP, Accardo S, Reginster JY, et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001;50(Suppl 1):S30-4
   PubMedGoogle Scholar
• Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J Rheumatol 1998;27:32-7
   PubMed Web of Science ®Google Scholar
• Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;35(Suppl 1):35-8
   PubMedGoogle Scholar
• Goei Thè HS, Lund B, Distel MR, et al. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5:283-8
   PubMed Web of Science ®Google Scholar
• Chang DM, Young TH, Hsu CT, et al. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin Rheumatol 2001;20:104-13
   PubMed Web of Science ®Google Scholar
• Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51
   PubMedGoogle Scholar
• Girawan D, Abdurachman SA, Djumhana A, et al. Comparison of endoscopic gastric mucosa features after administration of piroxicam to meloxicam and their correlation with dyspepsia symptoms in elderly patient with knee osteoarthritis. Acta Med Indones 2004;36:202-6
   PubMedGoogle Scholar
• Layton D, Hughes K, Harris S, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford) 2003;42:1354-64
   PubMed Web of Science ®Google Scholar
• MOBIC (meloxicam) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2006
   Google Scholar
• van der Linden MW, van der Bij S, Welsing P, et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2009;68:668-73
   PubMed Web of Science ®Google Scholar
• Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs. non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 2007;46:435-8
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Cryer B, Amer F, et al. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007;5:1167-74
   PubMed Web of Science ®Google Scholar
• Huang WF, Hsiao FY, Wen YW, et al. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Clin Ther 2006;28:1827-36
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008;59:1097-104
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169:141-9
   PubMed Web of Science ®Google Scholar
• Prevacid Naprapac (naproxen/lansoprazole) [package insert]. Lake Forest, IL: TAP Pharmaceuticals, 2008
   Google Scholar
• Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31:260-71
   PubMed Web of Science ®Google Scholar
• Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage 2007;15:1348-56
   PubMed Web of Science ®Google Scholar
• Combunox (oxycodone hydrochloride/ibuprofen) [package insert]. New York, NY: Forest Laboratories, Inc., 2007
   Google Scholar
• Litkowski LJ, Christensen SE, Adamson DN, et al. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate-to-severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model. Clin Ther 2005;27:418-29
   PubMed Web of Science ®Google Scholar
• Van Dyke T, Litkowski LJ, Kiersch TA, et al. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of postoperative pain: a double-blind, placebo- and active-controlled parallel-group study. Clin Ther 2004;26:2003-14
   PubMed Web of Science ®Google Scholar
• Singla N, Pong A, Newman K, et al. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study. Clin Ther 2005;27:45-57
   PubMed Web of Science ®Google Scholar
• Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6
   PubMed Web of Science ®Google Scholar
• Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2:155-63
   PubMed Web of Science ®Google Scholar
• Barthel HR, Haselwood D, Longley S 3rd, et al. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum 2009;39:203-12
   PubMed Web of Science ®Google Scholar
• Altman RD, Dreiser RL, Fisher CL, et al. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:1991-9
   PubMed Web of Science ®Google Scholar
• Pennsaid (diclofenac sodium topical solution) 1.5% w/w [prescribing information]. Hazelwood, MO: Mallinckrodt, Inc., 2010
   Google Scholar
• Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005;6:44
   PubMed Web of Science ®Google Scholar
• Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004;171:333-8
   PubMed Web of Science ®Google Scholar
• Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (PENNSAID) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004;164:2017-23
   PubMed Web of Science ®Google Scholar
• Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009;143:238-45
   PubMed Web of Science ®Google Scholar
• Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (PENNSAID) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002-12
   PubMed Web of Science ®Google Scholar
• Shainhouse JZ, Grierson LM, Naseer Z. A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther 2010;17:566-76
   PubMed Web of Science ®Google Scholar